May 22, 2024, 01:03
Nicholas Hornstein: The first trial to demonstrate benefit of systemic therapy in appendiceal cancer
Nicholas Hornstein, Oncology Fellow at MD Anderson Cancer Centre, shared a post by Cancer Research Communications on X, adding:
“Pleased to announce the first trial to demonstrate benefit of systemic therapy in appendiceal cancer. Atezolizumab and Bevacizumab; significantly improved PFS compared to synthetic cohort.
Median PFS 18.3 vs 4.4 months. Thanks to John Paul Shen and Kanwal Raghav for mentorship.” .
Quoting Cancer Research Communications’ post:
“Just published: Efficacy and safety of atezolizumab and bevacizumab in appendiceal adenocarcinoma, by Nicholas Hornstein et al.”
Source: Nicholas Hornstein/X and Cancer Research Communications/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19